Quince Therapeutics CEO and COO to Resign, Orphai Leadership to Take Over Pending Stockholder Vote
QNCX sits 54% above its 52-week low of $15.1.
Summary
Quince Therapeutics' CEO and COO will resign if stockholders approve the Orphai acquisition-related proposals at a September 25 Special Meeting, handing leadership to Orphai's former CEO, CFO, and COO. The vote is make-or-break for the company's strategic direction.
Key Events · Executive and Board Changes · QNCX
-
CEO and COO Conditional Resignations
CEO/CMO Dirk Thye and COO/CBO/CCO Brendan Hannah will resign two business days after the September 25, 2026 Special Meeting, but only if stockholders approve the Conversion, Minimum Price, and Authorized Share proposals.
-
Orphai Leadership Appointed as Successors
Brigette Roberts (Orphai's former CEO) becomes CEO, John Militello becomes CFO, and Keith Fandrick becomes COO, effective upon the resignations — a complete leadership transition to the acquired company's team.
-
High-Stakes Stockholder Vote
The resignations are contingent on approval of three proposals tied to the Orphai acquisition and PIPE financing, including an increase in authorized shares from 250M to 275M. A 'no' vote could leave the company without its CEO and COO.
-
Board Size Reduction
The board will shrink from five to four directors upon Thye's resignation, with the company intending to appoint an independent director later.
Analysis · QNCX · Life Sciences
Quince Therapeutics' CEO/CMO Dirk Thye and COO/CBO/CCO Brendan Hannah have tendered conditional resignations, effective only if stockholders approve three critical proposals at a September 25 Special Meeting. The proposals — authorizing share issuance for the Orphai acquisition and PIPE financing, and increasing authorized shares — are the final steps to complete the transformative Orphai deal. If approved, Orphai's former CEO Brigette Roberts becomes CEO, and Orphai's finance and operations heads take over as CFO and COO. This is a complete leadership handover to the acquired company's team, signaling that Quince's future is now entirely tied to Orphai's pulmonary pipeline. The resignations are contingent on stockholder approval, creating a high-stakes vote: a 'no' vote could leave the company without its top executives. The board also shrinks from five to four directors, with plans to add an independent director later.
At the time of this filing, QNCX was trading at $23.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.9M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.